Pfizer announced positive topline Phase 2 results for Atirmociclib, a next-generation CDK4 inhibitor, in second-line metastatic breast cancer on March 9, 20263
Atirmociclib is being developed as a potential treatment option for patients with metastatic breast cancer who have progressed on prior therapies3
The drug represents part of Pfizer's pipeline expansion in oncology, with 2026 serving as a catalyst-rich year for the company's drug development programs7
Sources:
3. https://www.pfizer.com/newsroom/press-releases
7. https://finviz.com/news/303069/pfizer-bets-big-on-obesity-and-oncology-with-2026-pipeline-push